Brief: Neurobo Pharmaceuticals Announces FDA Clearance Of IND For Phase 1 Clinical Trial Of DA-1726

MetaVia

01/02/2024 14:09

Feb 1 (Reuters) - Neurobo Pharmaceuticals Inc  NRBO.O :
    * NEUROBO PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR
A
PHASE 1 CLINICAL TRIAL OF DA-1726 FOR THE TREATMENT OF OBESITY
    * NEUROBO PHARMACEUTICALS INC - INITIATION OF PHASE 1
CLINICAL
TRIAL EXPECTED TO OCCUR IN FIRST HALF OF 2024
    * NEUROBO PHARMACEUTICALS INC - BELIEF THAT DA-1726 MAY HAVE
A
BETTER TOLERABILITY PROFILE THAN CURRENTLY AVAILABLE GLP-1
AGONISTS

Source text for Eikon:  ID:nPn6g3nRza 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))